CASTRATION-RESISTANT PROSTATE CANCER

This study looks at the best timing for combining targeted radiation (SBRT) with hormone therapy in men whose prostate cancer has returned and spread. It also tests if radiation to the pelvis can stop cancer from spreading further. About 532 men with recurrent, hormone-sensitive …

This study is for men with a specific type of advanced prostate cancer that has stopped responding to standard hormone therapy. The treatment combines high-dose testosterone with a chemotherapy drug called carboplatin. The goal is to see if this approach can lower PSA levels and …

This study tests whether adding a drug called carotuximab to the standard treatment apalutamide can help men with a type of advanced prostate cancer that has stopped responding to previous therapies. About 100 participants will be enrolled to see if the combination delays cancer …

This study tests whether combining two drugs, cabozantinib and nivolumab, can slow the growth of advanced prostate cancer that has stopped responding to hormone therapy. About 47 men with metastatic castration-resistant prostate cancer will receive the combination. The main goal …

This early-stage trial tests an experimental drug called GZ17-6.02 in 30 men with castration-resistant prostate cancer that has worsened despite hormone therapy. The main goal is to see if the drug can delay cancer growth for at least 6 months. Researchers will also measure chang…

This early-stage trial tests a new oral drug, DCC-2812, in about 60 people with advanced kidney, bladder, or prostate cancer that has spread or stopped responding to standard treatments. The main goals are to check safety and find the right dose, while also watching for any tumor…

This early-stage study tests a new drug called IDE034 in 150 adults with advanced solid tumors (like lung, ovarian, or colon cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors…

This early-stage study tests a new drug called JANX014 in about 43 men with a hard-to-treat type of prostate cancer that has spread and no longer responds to hormone therapy. The main goals are to check the drug's safety and find the right dose, while also looking for any signs t…

This study tests a new radioactive drug (161Tb-RAD402) designed to find and attack prostate cancer cells that no longer respond to standard hormone therapy. About 73 men with castration-resistant prostate cancer will receive the drug to see if it is safe and can shrink tumors or …

This study follows 120 men with advanced prostate cancer to see if markers in their blood can predict how well they respond to hormone therapy. Researchers will collect blood samples and compare markers from those who respond well to those who don't. The goal is to develop a test…

This study looks at how hormonal therapy changes a protein called PSMA in prostate cancer cells, both in cancers that respond to hormone treatment and those that don't. Researchers will track 80 men with prostate cancer to see how PSMA levels change shortly after starting therapy…